These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14745704)

  • 1. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.
    Belshe RB; Newman FK; Tsai TF; Karron RA; Reisinger K; Roberton D; Marshall H; Schwartz R; King J; Henderson FW; Rodriguez W; Severs JM; Wright PF; Keyserling H; Weinberg GA; Bromberg K; Loh R; Sly P; McIntyre P; Ziegler JB; Hackell J; Deatly A; Georgiu A; Paschalis M; Wu SL; Tatem JM; Murphy B; Anderson E
    J Infect Dis; 2004 Feb; 189(3):462-70. PubMed ID: 14745704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.
    Karron RA; Belshe RB; Wright PF; Thumar B; Burns B; Newman F; Cannon JC; Thompson J; Tsai T; Paschalis M; Wu SL; Mitcho Y; Hackell J; Murphy BR; Tatem JM
    Pediatr Infect Dis J; 2003 May; 22(5):394-405. PubMed ID: 12792378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.
    Lee MS; Greenberg DP; Yeh SH; Yogev R; Reisinger KS; Ward JI; Blatter MM; Cho I; Holmes SJ; Cordova JM; August MJ; Chen W; Mehta HB; Coelingh KL; Mendelman PM
    J Infect Dis; 2001 Oct; 184(7):909-13. PubMed ID: 11509996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIV-3 vaccine National Institutes of Health/Aviron.
    Jones T
    Curr Opin Investig Drugs; 2001 Jul; 2(7):890-2. PubMed ID: 11757785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
    Englund JA; Karron RA; Cunningham CK; Larussa P; Melvin A; Yogev R; Handelsman E; Siberry GK; Thumar B; Schappell E; Bull CV; Chu HY; Schaap-Nutt A; Buchholz U; Collins PL; Schmidt AC;
    Vaccine; 2013 Nov; 31(48):5706-12. PubMed ID: 24103895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.
    Madhi SA; Cutland C; Zhu Y; Hackell JG; Newman F; Blackburn N; Murphy BR; Belshe RB; Karron RA; Deatly AM; Gruber WC; Bernstein DI; Wright PF
    Vaccine; 2006 Mar; 24(13):2432-9. PubMed ID: 16406170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies.
    Durbin AP; Cho CJ; Elkins WR; Wyatt LS; Moss B; Murphy BR
    J Infect Dis; 1999 Jun; 179(6):1345-51. PubMed ID: 10228053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.
    Greenberg DP; Walker RE; Lee MS; Reisinger KS; Ward JI; Yogev R; Blatter MM; Yeh SH; Karron RA; Sangli C; Eubank L; Coelingh KL; Cordova JM; August MJ; Mehta HB; Chen W; Mendelman PM
    J Infect Dis; 2005 Apr; 191(7):1116-22. PubMed ID: 15747247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents.
    Bergen R; Black S; Shinefield H; Lewis E; Ray P; Hansen J; Walker R; Hessel C; Cordova J; Mendelman PM
    Pediatr Infect Dis J; 2004 Feb; 23(2):138-44. PubMed ID: 14872180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.
    Phua KB; Quak SH; Lee BW; Emmanuel SC; Goh P; Han HH; De Vos B; Bock HL
    J Infect Dis; 2005 Sep; 192 Suppl 1():S6-S16. PubMed ID: 16088807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S; Vertruyen A; Arístegui J; Esposito S; McKeith DD; Klemola T; Biolek J; Kühr J; Bujnowski T; Desgrandchamps D; Cheng SM; Skinner J; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2006 Oct; 25(10):870-9. PubMed ID: 17006279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
    Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
    J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
    Skiadopoulos MH; Surman S; Tatem JM; Paschalis M; Wu SL; Udem SA; Durbin AP; Collins PL; Murphy BR
    J Virol; 1999 Feb; 73(2):1374-81. PubMed ID: 9882342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.
    Durbin AP; Wyatt LS; Siew J; Moss B; Murphy BR
    Vaccine; 1998 Aug; 16(13):1324-30. PubMed ID: 9682397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.
    Karron RA; Wright PF; Newman FK; Makhene M; Thompson J; Samorodin R; Wilson MH; Anderson EL; Clements ML; Murphy BR
    J Infect Dis; 1995 Dec; 172(6):1445-50. PubMed ID: 7594701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
    Sabchareon A; Lang J; Chanthavanich P; Yoksan S; Forrat R; Attanath P; Sirivichayakul C; Pengsaa K; Pojjaroen-Anant C; Chambonneau L; Saluzzo JF; Bhamarapravati N
    Pediatr Infect Dis J; 2004 Feb; 23(2):99-109. PubMed ID: 14872173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of weanling hamsters from experimental infection with wild-type parainfluenza virus type 3 (para 3) by cold-adapted mutants of para 3.
    Crookshanks-Newman FK; Belshe RB
    J Med Virol; 1986 Feb; 18(2):131-7. PubMed ID: 3005486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children.
    Kim HW; Arrobio JO; Brandt CD; Wright P; Hodes D; Chanock RM; Parrott RH
    Pediatrics; 1973 Jul; 52(1):56-63. PubMed ID: 4353352
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.